Yonghong Wang

Dr. Yonghong Wang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YWYonghong Wang
Yonghong Wang
YJYanru Jia
Yanru Jia
XYXin Yang
Xin Yang
BLBin Liang
Bin Liang
HGHongjuan Gao
Hongjuan Gao
TYTaotao Yang
Taotao Yang
The incidence of acute liver and kidney injury in pregnancy is companied by Preeclampsia (PE), which has remained a major cause of maternal and fetal morbidity, and mortality. Therefore, a significant treatment to protect against liver and kidney injury of PE requires new drugs to develop potential therapeutic benefits to the clinic. Baicalin played protection role on inhibition of cell apoptosis which is a potential drug for keep liver and kidney from acute injury on PE patients. In this study, we made PE rat disease model with liver and kidney acute injury, and then used low-, medium-, and high-dose of Baicalin to treat PE rat, respectively. We found that Baicalin attenuated acute injury symptoms and inhibited apoptosis of rat liver and kidney tissues. The intervention of Baicalin increased the expression of anti-apoptotic protein XIAP and Bcl-2, reduced the expression of apoptotic protein Caspase-9 in rat liver; and similarly, Baicalin increased the expression of Bcl-2, while inhibited Caspase-9 and AT1 in rat kidney. Interestingly, Baicalin intervention with medium dose showed a better function for inhibiting apoptosis. Our data suggests that Baicalin is a potentially therapeutic candidate for preventing liver and kidney damage, which shed a light on therapeutic benefit for PE rat models.

6 December 2019 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
JYJing Yang
Jing Yang
WWWei Wang
Wei Wang
ZWZhe Wang
Zhe Wang
ZWZhilian Wang
Zhilian Wang
YWYonghong Wang
Yonghong Wang
MHMin Hao
Min Hao
Human papillomavirus(HPV) infection is a necessary factor for the development of cervical cancer. The HPV vaccine is currently available, but there is still a lack of large-scale research on the distribution and risk factors of HPV. The aim of this study is to investigate the genotype distribution and risk factors of HPV infection in Yangqu which is located in North China. This study enrolled 10086 women aged <65 years from Yangqu County. HPV genotypes were identified via standard HPV DNA testing. The overall prevalence of HPV infection was 8.92%. The prevalence of high-risk HPV types was 8.80%, and it was 0.38% for low-risk HPV types. Single genotype infection accounted for 67.91% in HPV-positive cases. The most common HPV genotypes were HPV-16, −52, and −58. HPV-18 was only the 11th most common type in HPV-positive cases. Women ≥50 years of age had the highest prevalence rate of HPV, and women <30 years had the lowest prevalence rate. The distribution of HPV genotypes also varied among the three age groups: <30, 30–49, and ≥50 years. The risk factors that contributed to the rate of HPV infection included low educational level, low income, smoking, age at first sexual encounter <23 years old, and number of births ≥3 times. This large routine clinical practice report of HPV prevalence and genotype distribution revealed the characteristics of HPV infection-type distributions in Shanxi Province, which should be considered in formulating comprehensive prevention strategies including vaccination for cervical cancer in China.

30 March 2016 in European Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
WZW Zhao
W Zhao
MHMin Hao
Min Hao
YWYonghong Wang
Yonghong Wang
NFN Feng
N Feng
ZWZ Wang
Z Wang
LDL Ding
L Ding
To investigate the effect of folate status on cervical intraepithelial neoplasia (CIN) progression and its relationship with high-risk human papillomavirus (hrHPV). We evaluated 20 000 sexually active women aged <65 years in Yangqu County by using a questionnaire; the subjects were also screened using the ThinPrep cytologic test (TCT). Patients with abnormal TCT results (other than glandular cell abnormalities) who were willing to provide informed consent were further diagnosed using colposcopy and histopathological examination. We investigated 247 cases of low-grade cervical squamous intraepithelial lesions (LSIL), 125 cases of high-grade cervical squamous intraepithelial lesions (HSIL) and 877 controls. A 24-item food frequency questionnaire was filled out by the investigator to estimate the consumption of dietary folate. Positivity for hrHPV from residual exfoliated cervical cells was tested; serum folate was also measured. The hrHPV infection rate in HSIL patients (77.6%) was higher than that in LSIL (33.2%) and control (32.0%) patients. Dietary folate intakes in controls, LSIL and HSIL were 306.9±176.6, 321.8±168.0 and 314.7±193.8 μg/kcal, respectively. The levels of serum folate in controls, LSIL and HSIL were 18.2±7.9, 15.9±7.1 and 14.3±7.5 nmol/l, respectively. Increased CIN correlated with higher rates of hrHPV infection and lower levels of serum folate. Low levels of serum folate may increase the risk of CIN progression. Furthermore, potential synergy may exist between low serum folate levels and hrHPV infection to promote CIN development.

1 July 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YWYonghong Wang
Yonghong Wang
KCKeyan Cheng
Keyan Cheng
WZWenli Zhou
Wenli Zhou
HLHuiqiang Liu
Huiqiang Liu
TYTaotao Yang
Taotao Yang
XLXiaowei Li
Xiaowei Li
Preeclampsia is a pregnancy-specific syndrome characterized by hypertension and proteinuria. Impaired trophoblast invasion partly modulated by abnormal MAPK1/ERK2 signaling played important roles in the pathological process of preeclampsia. The objective of this study is to investigate miR-141-5p regulate ATF2 via effecting MAPK1/ERK2 signaling to promote preeclampsia. The maternal placentae and clinical data of 30 patients with preeclampsia and 30 healthy pregnant women were collected in the Second Hospital of Shanxi Medical University from July 2015 to April 2016. Transcriptional levels of miR-141-5p in placentae were monitored using quantitative real-time reverse transcription-polymerase chain reaction. The target gene of miR-141-5p was analyzed with "TargetScanHuman Release 7.2″. To evaluate the pathways of this response, MAPK1 and ERK1/2 in placentae were detected using immunohistochemistry and Western Blot. Transfection experiment was used to verify the function of miR-141-5p regulating ATF2 to effect MAPK1/ERK2 signaling in JEG-3 cells. miR-141-5p was significantly down-regulated in placentae of patients with preeclampsia, in comparison to the healthy pregnant women groups. There was no difference in MAPK1 expression between placentae of patients with preeclampsia and healthy pregnant women groups. While p-MAPK1 expression was lower in preeclampsia placentae, in comparison to the healthy pregnant women groups. Moreover, inhibition and activation experiments also validate the function of miR-141-5p in effecting p-MAPK1 level in JEG-3 cells. Bioinformatic analysis identified that ATF2 was a target gene of miR-141-5p, which was one DNA-binding protein to effect phosphatase DUSP1 transcription. DUSP1 effect MAPK1/ERK2 signaling in preeclampsia. miR-141-5p up-regulated transcription factor ATF2 to promote phosphatase DUSP1 expression. DUSP1 expression reduces p-MAPK1 and ERK1/2 expression to promote preeclampsia.

2 February 2017 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Open access
PDF file
YWYonghong Wang
Yonghong Wang
MHMin Hao
Min Hao
SSStephanie Sampson
Stephanie Sampson
JXJun Xia
Jun Xia
Purpose To evaluate the effectiveness and safety of elective delivery versus expectant management for women with pre-eclampsia (PE) and to assess neonatal outcomes before and after 34 weeks gestation. Methods We searched Biomed Central, CINAHL, Cochrane Library, Embase, HMIC, Medline, and WHO trial registry, British Nursing Index, ClinicalTrials.gov, Current Controlled Trials, and Web of Science on 16 March, 2016. 1704 citations were identified. Randomised controlled trials comparing elective delivery with expectant management for women with PE were included. Seven studies were included (n = 1501). There were no maternal deaths. Results Elective delivery lowered incidence of complications in women with PE or hypertension greater than 34 weeks gestation (n = 756; RR, 0.64; 95% CI 0.51–0.80). For women with severe PE less than 34 weeks gestation, elective delivery lowered the incidence of placental abruption (n = 483, 5 RCTs; RR, 0.43; 95% CI 0.19–0.98). For women with PE or hypertension greater than 34 weeks gestation, elective delivery also reduced the need for antihypertensive drug therapy. The need for ventilatory support and the risk of developing neonatal intraventricular hemorrhage or hypoxic ischemic encephalopathy may be increased in infants whose mothers undergo elective delivery for severe PE at less than 34 weeks gestation. However, there was no relevant evidence for women with severe PE over 34 weeks. Conclusions In women with PE or gestational hypertension beyond 34 weeks gestation, elective delivery can decrease the incidence of complications, severe hypertension and the need for antihypertensive drug therapy. Elective delivery can also lower the risk of placental abruption in women before 34 weeks gestation with severe PE, however, may be associated with increased risk of neonatal complications.

24 September 2019 in Lupus
Verified
Journal Article
Closed access
PDF file
YCY Chu
Y Chu
CZC Zhao
C Zhao
BZB Zhang
B Zhang
XWX Wang
X Wang
YWYonghong Wang
Yonghong Wang
JCJ Chen
J Chen
This study aimed to investigate the effect of rapamycin (RAPA) alone or in combination with all-trans retinoic acid (ATRA) on the T-helper 17 (Th17) cell/regulatory T-cell (Treg) balance in patients with systemic lupus erythematosus (SLE) and to evaluate the clinical efficacy. Seventy patients with SLE were enrolled. They were randomly and equally divided into RAPA and RAPA + ATRA groups. The number of Th17 and Treg cells was measured by flow cytometry before and after treatment for 6, 12 and 24 weeks. The SLE Disease Activity Index (SLEDAI) score and the prednisone dose before and after treatment were used to evaluate the efficacy between the two groups. In both groups, at different time points after treatment, the number of Th17 cells (p = 0.003) and Th17/Treg ratio (p = 0.044) reduced, while the number of Treg cells (p = 0.574) tended to increase. The SLEDAI score and the dose of prednisone decreased significantly (p < 0.001). There was no significant difference in the number of Th17 cells (p = 0.089), Treg cells (p = 0.059), Th17/Treg ratio (p = 0.580), SLEDAI score (p = 0.127) and the dose of prednisone (p = 0.329) between the two groups. Disease activity in SLE patients reduced with RAPA alone or in conjunction with ATRA, reducing glucocorticoid requirement. One of its mechanisms of action may be regulating the Th17/Treg cell balance, which provides a new model for the pathogenesis and potential treatment of SLE.